Anacetrapib reduces progression of atherosclerosis, mainly by reducing non-HDL-cholesterol, improves lesion stability and adds to the beneficial effects of atorvastatin

Author(s):
Kuhnast, S.; Tuin, S.J.L. van der; Hoorn, J.W.A. van der; Klinken, J.B. van; Simic, B.; Pieterman, E.; Havekes, L.M.; Landmesser, U.; Luscher, T.F.; Dijk, K.W. van; Rensen, P.C.N. (0000-0002-8455-4988); Jukema, J.W. (0000-0002-3246-8359); Princen, H.M.G.
Published
2015
Publication type
Article / Letter to editor
Cholesteryl ester transfer proteinNon-HDL-cholesterolHDL-cholesterolHDL functionAtherosclerosisAnacetrapibAtorvastatin
Date issued
2015-01-31
Language
English
Is part of
European Heart Journal (2015), Vol. 36, no. 1, p. 39-48A
hdl
1887/105518
doi
10.1093/eurheartj/ehu319